Carestream Highlights Vital Advancements in Mobile Imaging at RSNA 2021

Carestream Health will showcase its innovations in mobile medical imaging with the Ziehm Vision RFD C-arm and DRX-Revolution Mobile X-ray System at the Radiological Society of North America (RSNA) conference in Chicago, Ill.

Ca Restream Highlights Vital Advancements In Mobile Imaging At Rsna 2021With a continued focus on advanced diagnostic imaging, Carestream recently added the Ziehm Vision RFD C-arm System to its product portfolio. A mobile, fluoroscopic surgical imaging system with a flat-panel detector, the Ziehm Vision RFD C-arm allows for broad procedural work including vascular, cardiac, spine ortho-trauma and pain management, in addition to many general surgical applications. The system’s Advanced Active Cooling enables extended case times beyond traditional air-cooled systems. It also provides an intuitive graphical interface that benefits technologists with reduced training time as well as improved productivity.Carestream offers this system in partnership with Ziehm Imaging, bolstering its mobile and fluoroscopic product offerings to further benefit healthcare providers.

Carestream’s enhanced DRX-Revolution Mobile X-ray System has an improved ergonomic design and streamlineduser workflow, as well as functional LED lighting and more responsive display screens. Dedicated to both patient and provider safety, Carestream’s mobile solution plays an instrumental role in limiting the potential spread of infectiousdiseases by allowing operators to complete all general imaging examinations at the bedside.

Carestream’s mobile and fluoroscopic product offerings deliver high-quality diagnostic images at the bedsidewhether that is in the ICU, OR or anywhere elsereducingthe need to transport patients throughout a facility,” said Jorge Quant, VP Strategy and Marketing, Americas Region and Global Marketing Director at Carestream. Both the Ziehm Vision RFD C-arm and our mobile DRX-Revolution are examples of Carestreams commitment to meet the evolving needs of our customers and their patients.

To learn more about Carestreams continuous advances in mobile imaging, stop by the Carestream booth #7316 in North Hall during RSNA 2021.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”